BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

780 related articles for article (PubMed ID: 24684824)

  • 1. Anti-obesity effects of KR-66195, a synthetic DPP-IV inhibitor, in diet-induced obese mice and obese-diabetic ob/ob mice.
    Lee EY; Kim YW; Oh H; Choi CS; Ahn JH; Lee BW; Kang ES; Cha BS; Lee HC
    Metabolism; 2014 Jun; 63(6):793-9. PubMed ID: 24684824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel dipeptidyl peptidase-4 inhibitor teneligliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in mice.
    Fukuda-Tsuru S; Kakimoto T; Utsumi H; Kiuchi S; Ishii S
    Eur J Pharmacol; 2014 Jan; 723():207-15. PubMed ID: 24309217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S 23521 decreases food intake and body weight gain in diet-induced obese rats.
    Claret M; Corominola H; Canals I; Nadal B; Chavanieu A; Pfeiffer B; Renard P; Gorostiaga C; Delagrange P; Grassy G; Gomis R
    Obes Res; 2004 Oct; 12(10):1596-603. PubMed ID: 15536223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
    Moritoh Y; Takeuchi K; Hazama M
    J Pharmacol Exp Ther; 2009 May; 329(2):669-76. PubMed ID: 19208898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KR-62436, 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity.
    Kim KR; Rhee SD; Kim HY; Jung WH; Yang SD; Kim SS; Ahn JH; Cheon HG
    Eur J Pharmacol; 2005 Jul; 518(1):63-70. PubMed ID: 16106524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
    Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
    J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GLP-1-derived nonapeptide GLP-1(28-36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice.
    Tomas E; Wood JA; Stanojevic V; Habener JF
    Regul Pept; 2011 Aug; 169(1-3):43-8. PubMed ID: 21549160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob mice.
    Irwin N; Montgomery IA; Moffett RC; Flatt PR
    Biochem Pharmacol; 2013 Jan; 85(1):81-91. PubMed ID: 23085436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-diabetic and anti-inflammatory effect of a novel selective 11β-HSD1 inhibitor in the diet-induced obese mice.
    Park SB; Jung WH; Kang NS; Park JS; Bae GH; Kim HY; Rhee SD; Kang SK; Ahn JH; Jeong HG; Kim KY
    Eur J Pharmacol; 2013 Dec; 721(1-3):70-9. PubMed ID: 24135201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.
    Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
    Eur J Pharmacol; 2008 Jul; 588(2-3):325-32. PubMed ID: 18499100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
    Irwin N; McClean PL; Flatt PR
    J Pept Sci; 2007 Jun; 13(6):400-5. PubMed ID: 17486662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of sleeve gastrectomy on body weight, food intake, glucose tolerance, and metabolic hormone level in two different rat models: Goto-Kakizaki and diet-induced obese rat.
    Trung VN; Yamamoto H; Yamaguchi T; Murata S; Akabori H; Ugi S; Maegawa H; Tani T
    J Surg Res; 2013 Nov; 185(1):159-65. PubMed ID: 23746960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel black soy peptides with antiobesity effects: activation of leptin-like signaling and AMP-activated protein kinase.
    Jang EH; Moon JS; Ko JH; Ahn CW; Lee HH; Shin JK; Park CS; Kang JH
    Int J Obes (Lond); 2008 Jul; 32(7):1161-70. PubMed ID: 18414417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse.
    Bahrami J; Longuet C; Baggio LL; Li K; Drucker DJ
    Gastroenterology; 2010 Sep; 139(3):857-68. PubMed ID: 20546737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of exercise and food restriction on obesity and diabetes in young ob/ob mice.
    Dubuc PU; Cahn PJ; Willis P
    Int J Obes; 1984; 8(3):271-8. PubMed ID: 6378818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amylin improves the effect of leptin on insulin sensitivity in leptin-resistant diet-induced obese mice.
    Kusakabe T; Ebihara K; Sakai T; Miyamoto L; Aotani D; Yamamoto Y; Yamamoto-Kataoka S; Aizawa-Abe M; Fujikura J; Hosoda K; Nakao K
    Am J Physiol Endocrinol Metab; 2012 Apr; 302(8):E924-31. PubMed ID: 22275759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of genetically obese mice with the iminosugar N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin reduces body weight by decreasing food intake and increasing fat oxidation.
    Langeveld M; van den Berg SA; Bijl N; Bijland S; van Roomen CP; Houben-Weerts JH; Ottenhoff R; Houten SM; van Dijk KW; Romijn JA; Groen AK; Aerts JM; Voshol PJ
    Metabolism; 2012 Jan; 61(1):99-107. PubMed ID: 21816446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour.
    Smith GC; Vickers MH; Cognard E; Shepherd PR
    Schizophr Res; 2009 Nov; 115(1):30-40. PubMed ID: 19679451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, suppresses high fat diet-induced obesity and glucose intolerance in Sprague-Dawley rats.
    Hata T; Mera Y; Tadaki H; Kuroki Y; Kawai T; Ohta T; Kakutani M
    Diabetes Obes Metab; 2011 May; 13(5):446-54. PubMed ID: 21255216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
    Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
    Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.